PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • Advertisement
  • FDA Date: 02/23/2015

    Farydak (panobinostat) REMS

    Goal of the Farydak (panobinostat) REMS Program

    The goal of the FARYDAK REMS is to mitigate the risks of severe diarrhea and cardiac toxicities (severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes) associated with FARYDAK treatment
    • by informing healthcare providers about the risks of severe diarrhea and cardiac toxicities associated with FARYDAK

    REMS Elements

    • Communication Plan